Clinical Trials Logo

Filter by:
NCT ID: NCT06190808 Not yet recruiting - Diabetes Mellitus Clinical Trials

Continuous Glucose Monitoring in the Intensive Care Unit

Start date: January 2, 2024
Phase: N/A
Study type: Interventional

The aim of the proposed clinical trial is to study the use of the Dexcom G7 continuous glucose monitor (CGM) within the intensive care unit (ICU) environment. The overall goal is to validate the accuracy and practicality of the Dexcom G7 when used to assess glycemia in critically ill patients.

NCT ID: NCT06190717 Recruiting - Diabetes Clinical Trials

Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

MAFASA
Start date: February 21, 2024
Phase: N/A
Study type: Interventional

This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation.

NCT ID: NCT06190691 Completed - Healthy Clinical Trials

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

Start date: December 18, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired liver function and healthy participants. The side effects and tolerability of pirtobrutinib will also be evaluated. Participation could last about 46 days.

NCT ID: NCT06190678 Completed - Healthy Clinical Trials

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants

Start date: February 1, 2021
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired kidney function and healthy participants. The side effects and tolerability of pirtobrutinib will also be evaluated. Participation could last around 46 days.

NCT ID: NCT06190561 Completed - Healthy Clinical Trials

A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults

Start date: January 15, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare two finished products of PF-07940367 in terms of the uptake into the blood stream. This study is seeking participants who are: - Healthy male or female participants aged 18 years or older. All participants in this study will receive PF-07940367 once by mouth. The participants may receive different tablets by mouth for PF-07940367. The study will compare experiences of people receiving two different products of PF-07940367. This will help understand how much PF-07940367 is taken up into the blood for each product given. Participants will take part in the study for about 112 days. During this time, participants will have to stay onsite for 5 days. There will be up to 2 additional onsite study visits and 3 remote (telephone call) study visits.

NCT ID: NCT06190379 Completed - Immune System Clinical Trials

Aromatherapy for Upper Respiratory Health

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to confirm and quantify the effects of aromatherapy on respiratory health.

NCT ID: NCT06190249 Suspended - Stage IIIC Melanoma Clinical Trials

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Start date: June 30, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the efficacy of adjuvant adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin-2 (IL-2) after a nonmyeloablative lymphodepletion (NMA-LD) preparative regimen, followed by Pembrolizumab.

NCT ID: NCT06190236 Recruiting - Clinical trials for Alcohol Use Disorder

Integration of Neurofunctional Phenotyping Into Investigation of CBT4CBT for AUD

Start date: April 10, 2024
Phase: N/A
Study type: Interventional

Alcohol use and misuse are prevalent in the United States. Alcohol use disorder (AUD) is the most common substance use disorder. Evidence-based treatments are effective; however, most people with AUD do not receive treatment, and among those who do, responses to treatment modalities vary. Technology provides the opportunity to expand treatment and improve outcomes. Therefore, the overall goal of this project is to incorporate neurofunctional phenotyping into a preliminary investigation of the feasibility of providing mobile CBT4CBT for AUD among a non-treatment seeking population

NCT ID: NCT06190197 Recruiting - Clinical trials for Muscle-Invasive Bladder Carcinoma

Prophylactic Antibiotics in Cystectomy With Diversion

Start date: May 13, 2024
Phase: Early Phase 1
Study type: Interventional

Using a randomized 2 arm design, this study is being conducted to test for non-inferiority of no prophylactic antibiotic therapy versus the prophylactic oral antibiotic, nitrofurantoin, through comparison of rates of postoperative urinary tract infections within the 90-day postoperative period in patients with muscle invasive bladder cancer who undergo radical cystectomy with urinary diversion.

NCT ID: NCT06190184 Recruiting - Depression Clinical Trials

Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Conditions

Start date: October 26, 2023
Phase: N/A
Study type: Interventional

US residents who have obesity and sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of two arms. This study is direct to participant and will not utilize clinical sites.